[Humoral immune response and in vitro neutralizing antibody assay on co-delivery of protein HPV16L1 virus-like particle with HPV16L1 gene].
OBJECTIVE
To compare humoral immune response by co-inoculating mice with antigen HPV16L1 virus-like particle (VLP) and HPV16L1 recombinant plasmids and then observing the neutralizing antibody activity in vitro.


METHODS
C57BL/6 mice were injected intramuscularly/subcutaneously with pcDNA-L1 plasmids plus HPV16L1 VLP. Serum IgG levels were detected by ELISA, antibody neutralizing protective activities were determined by hemagglutination inhibition and HPV16L1 VLP binding inhibition assay.


RESULTS
Serum antibody titers and neutralizing antibody activities were increased in HPV16L1 plasmids plus HPV16L1 VLP proteins in co-immunized mice when compared with controls.


CONCLUSIONS
Co-inoculation of the HPV16L1 VLP protein can enhance production of neutralizing antibody activities against aimed antigen, which should be a more promising strategy for effective HPV16 prophylactic vaccine development.
Song
Jian-ming
JM
Department of Pathology, Tumour Institute, Life Science and Technology School of Xi'an Jiaotong University, Xi'an 710061, China.
Sun
Xiang-le
XL
Wang
Yi-li
YL
Guo
Jian-fen
JF
Liu
Tian-ju
TJ
Si
Lü-sheng
LS
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D004903:Erythrocyte Aggregation; D005814:Genes, Viral; D006367:HeLa Cells; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007074:Immunoglobulin G / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D009500:Neutralization Tests; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000276:immunology*; D010957:Plasmids; D011994:Recombinant Proteins / Q000276:immunology
D000914:Antibodies, Viral; D036022:Capsid Proteins; D007074:Immunoglobulin G; D009856:Oncogene Proteins, Viral; D011994:Recombinant Proteins; C063317:L1 protein, Human papillomavirus type 16